---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-003136"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T08:28:44.065231+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Anika Therapeutics adds two directors, announces $40M buyback under Caligan deal

## Summary
- Appointed Joseph Capper (MIMEDX CEO) and William Jellison (former Stryker CFO) to Board; board expands to 10 then reduces to 9 after 2024 annual meeting.
- Authorized $40M share repurchase program: $15M via 10b5-1 by June 2025, remainder open market through June 2026, replacing April 2023 program.
- Caligan agrees to standstill, voting commitments, and other provisions under cooperation agreement.
- Reaffirmed 2024 adjusted EBITDA guidance of $25-30M, up >75% YoY at midpoint.
- New directors join Capital Allocation Committee; no prior relationships or transactions disclosed.

## SEC filing metadata
- accession: 0001171843-24-003136
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184324003136/0001171843-24-003136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184324003136/f8k_052824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-003136
- JSON: https://secwatch.observer/filing/0001171843-24-003136.json
- Plain text: https://secwatch.observer/filing/0001171843-24-003136.txt

## Key facts
- Executive change
  William Jellison was appointed as Director at Anika Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184324003136/0001171843-24-003136-index.htm
- Executive change
  Joseph Capper was appointed as Director at Anika Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184324003136/0001171843-24-003136-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.